In mammals, the vasopressin V 1b receptor (V 1b -R) is known to regulate ACTH secretion and, more recently, stress and anxiety. The characterization of the molecular determinant responsible for its pharmacological selectivity was made possible by the recent discovery of the first V 1b antagonist, SSR149415. Based upon the structure of the crystallized bovine rhodopsin, we established a threedimensional molecular model of interaction between the human V 1b -R (hV 1b -R) and SSR149415. Four amino acids located in distinct transmembrane helices (fourth, fifth, and seventh) were found potentially responsible for the hV 1b -R selectivity. To validate these assumptions, we selectively replaced the leucine 181, methionine 220, alanine 334, and serine 338 residues of hV 1a -R by their corresponding amino acids present in the hV 1b -R (phenylalanine 164, threonine 203, methionine 324, and asparagine 328, respectively). Four mutants, which all exhibited nanomolar affinities for vasopressin and good coupling to phospholipase C pathway, were generated. hV 1a receptors mutated at position 220 and 334 exhibited striking increase in affinity for SSR149415 both in binding and phospholipase C assays at variance with the hV 1a -R modified at position 181 or 338. In conclusion, this study provides the first structural features concerning the hV 1b -R and highlights the role of few specific residues in its pharmacological selectivity. (Molecular Endocrinology 18: 2777-2789, 2004) V ASOPRESSIN (AVP) IS A neurohypophysial hormone involved in a wide range of physiological actions including vasoconstriction, antidiuresis, and stimulation of ACTH (1), catecholamine (2), insulin, glucagon (3), and heart atrial natriuretic factor secretion (4). AVP is also supposed to regulate numerous central functions such as synaptic transmission, central control of body temperature, memory, and, more recently, anxiety and depression behaviors in the rat (5, 6).
In mammals, the vasopressin V 1b receptor (V 1b -R) is known to regulate ACTH secretion and, more recently, stress and anxiety. The characterization of the molecular determinant responsible for its pharmacological selectivity was made possible by the recent discovery of the first V 1b antagonist, SSR149415. Based upon the structure of the crystallized bovine rhodopsin, we established a threedimensional molecular model of interaction between the human V 1b -R (hV 1b -R) and SSR149415. Four amino acids located in distinct transmembrane helices (fourth, fifth, and seventh) were found potentially responsible for the hV 1b -R selectivity. To validate these assumptions, we selectively replaced the leucine 181, methionine 220, alanine 334, and serine 338 residues of hV 1a -R by their corresponding amino acids present in the hV 1b -R (phenylalanine 164, threonine 203, methionine 324, and asparagine 328, respectively). Four mutants, which all exhibited nanomolar affinities for vasopressin and good coupling to phospholipase C pathway, were generated. hV 1a receptors mutated at position 220 and 334 exhibited striking increase in affinity for SSR149415 both in binding and phospholipase C assays at variance with the hV 1a -R modified at position 181 or 338. In conclusion, this study provides the first structural features concerning the hV 1b -R and highlights the role of few specific residues in its pharmacological selectivity. (Molecular Endocrinology 18: 2777-2789, 2004) V ASOPRESSIN (AVP) IS A neurohypophysial hormone involved in a wide range of physiological actions including vasoconstriction, antidiuresis, and stimulation of ACTH (1), catecholamine (2) , insulin, glucagon (3) , and heart atrial natriuretic factor secretion (4) . AVP is also supposed to regulate numerous central functions such as synaptic transmission, central control of body temperature, memory, and, more recently, anxiety and depression behaviors in the rat (5, 6) .
This functional diversity is explained by interaction of AVP with three different specific receptor isoforms called V 1a , V 1b , and V 2 , on the basis of their pharmacological and G protein-coupling properties (for review see Refs. 1 and 7). The V 1a and V 1b subtypes are positively coupled to phospholipase C␤ and involved mainly in blood pressure control and regulation of ACTH secretion, respectively. The V 2 AVP receptor is coupled to adenylyl cyclase and is responsible for the antidiuretic effect of AVP. All these three receptor isoforms have been cloned and sequenced (for review see Ref. 8) . Whatever the species considered, they all share the structural characteristics of G proteincoupled receptors (GPCRs) including the seven ␣-helical transmembrane (TM) domains, which exhibit strong sequence similarities.
Over the past few years, many selective peptide and nonpeptide agonists or antagonists of AVP receptors exhibiting a good affinity have been characterized (9, 10) . For example, SR49059 and d[(CH 2 ) 5 Tyr(Me 2 )]AVP are both potent and selective V 1a antagonists with nanomolar affinities in various species (9) . Similarly, SR121463A is the best selective V 2 antagonist described (9) . Very recently d [Cha 4 ]AVP and SSR149415 were characterized as the first specific agonist and antagonist of the V 1b isoform, respectively (6, 11) .
Due to this wide range of physiological effects, high amino acid sequence homology, and complex phar-macological properties, the AVP receptor family represents an interesting system to investigate the functional molecular determinants of G protein-coupled receptor isoforms. Previous studies performed on AVP V 1a and V 2 receptor subtypes (V 1a -R and V 2 -R) have led to valuable information concerning the structure of the binding sites of many ligands. Thus, by mutational analysis and three-dimensional (3D) modeling, Mouillac and co-workers (12) have characterized the binding site of AVP in the human (h)V 1a -R. The hormonebinding site is located in a 15-20Å deep cleft surrounded by the top of the TM domains. Additional studies have further demonstrated that residues located in the first extracellular loop and in the N-terminal tail of the receptor also play a role in the binding of AVP (13, 14) . Because of the high conservation of the residues involved in the interaction with the hormone, this binding site has been proposed to be common to the three AVP receptor subtypes (12) . By using photoaffinity labeling, mutational analysis, and 3D molecular modeling approaches, structural information concerning the pharmacological specificity of the V 1a and V 2 receptor subtypes was also provided. These studies allowed the characterization of the binding sites of some V 1a and V 2 peptide or nonpeptide antagonists (15) (16) (17) (18) . They are located mainly in the top of the seventh TM domain (16) , in the first (17) and second extracellular (E2) loops (15) . Further studies performed on the V 1a and the V 2 receptors also led to the identification of residues that differentiate agonist vs. antagonist binding (14, 15, 19) .
At variance with the V 1a and V 2 receptor isoforms, no structural information about the V 1b subtype is available. This lack of structural data is due mainly to the absence of V 1b -specific pharmacological tools. Very recently, we synthesized [1-deamino, 4-cyclohexylalanine]AVP (d [Cha 4 ]AVP), the first specific peptidic agonist of nanomolar affinity for the hV 1b -R (11) . At the same time Serradeil-Le Gal et al. designed SSR149415, the first nonpeptide antagonist exhibiting an excellent affinity for this AVP receptor isoform (6) . These selective pharmacological tools have allowed the discovery of new V 1b -R functions. This AVP receptor isoform was thus shown to control some emotional behaviors. On various tests performed in the rat, SSR149415 exhibits potent anxiolytic and antidepressive effects similar to those induced by classical benzodiazepines or antidepressant drugs (20) . Such discovery was recently confirmed by the invalidation of this AVP receptor in mice (21) . These animals devoid of V 1b -Rs displayed a less aggressive behavior as compared with control (21) . At the peripheral level, the V 1b -Rs are also thought to be potent regulators of pancreas and adrenal functions by their ability to control insulin and catecholamine release respectively (22, 23) . The V 1b -R may thus represent a new target for drugs of therapeutic interest especially for the treatment of affective disorders. A better understanding of its molecular structure and of the binding mode of its ligands may then represent an important challenge to design new selective and potent drugs.
The purpose of this work is to propose and validate a 3D molecular model of the interactions between the antagonist SSR149415 and the hV 1b -R and to characterize the molecular determinants responsible for its ligand selectivity.
RESULTS

Alignment of Amino Acid Sequences and 3D Molecular Modeling
Aligning the amino acid sequences of both hV 1a and hV 1b AVP receptor subtypes with that of bovine rhodopsin is rather straightforward as rhodopsin-like fingerprints (e.g. NPxxY at TM7; see Ref. 24 ) are common to the three receptors. Of the 32 TM residues ( Fig.  1) supposed to map the TM binding cavity for receptor antagonists (25) , only nine differ between V 1a and V 1b AVP receptor subtypes. Interestingly, four of these residues are clustered in TM7.
The current hV 1b -R model was derived directly from a previously reported V 1a model that proved useful to discriminate known V 1a -R antagonists from randomly chosen drug-like molecules by high-throughput virtual screening (25) and to unambiguously determine the binding mode of the selective V 1a antagonist SR49059 by covalent labeling (26) . Automated docking of the selective V 1b antagonist SSR149415 suggests a binding mode between TMs 3, 5, 6, and 7 ( Fig. 2, A and B) . The three aromatic moieties of SSR149415 are embedded in three hydrophobic subsites (Fig. 2B) . The hydroxyl group of SSR149415 H-bonds to Gln301 side chain, which is conserved for V 1a and V 1b receptor subtypes, and its amide oxygen atom H bonds to Thr203 side chain at TM5. Of the nine abovementioned residues varying between hV 1a and hV 1b receptors, four amino acids (Phe164 on TM4, Thr203 on TM5, Met324 and Asn328 on TM7) are in close contact with SSR149415 in the proposed 3D model. Phe164 is unlikely to explain the V 1b selectivity of SSR149415 as it is mutated to a residue (Leu) in the V 1a -R that could interact similarly with the latter antagonist. The model suggests Thr203 and Met324 to be much more relevant. Hence, Thr203 and Met324 develop molecular interactions (H bond and hydrophobic contacts, respectively) with the V 1b -R, that are not possible with the V 1a subtype due to the observed amino acid mutations (Thr203 to Met, Met324 to Ala). Last, Asn328, which is part of the subsite predicted to interact with the dimethoxyphenyl moiety of SSR149415, and mutated to Ser in the V 1a -R, could also be a molecular determinant of the observed V 1b selectivity of the investigated antagonist. To validate these predictions, four residues (Phe164, Thr203, Met324, and Asn328) were thus selected for sitedirected mutagenesis.
Role of Specific Amino Acid Residues in hV 1b -R Selectivity: a Site-Directed Mutagenesis Approach
We selectively replaced the Leu181, Met220, Ala334, and Ser338 residues of hV 1a -R by their corresponding amino acids present in the hV 1b -R (Phe164,Thr203, Met324, and Asn328, respectively; Fig. 3 ). These mutants of the hV 1a -R were termed L181F, M220T, A334M, and S338N, respectively. As compared with the wild-type V 1a -R, they all bound [ 3 H]AVP with nanomolar affinities [dissociation constant (K d )] and were expressed to similar levels ( Table 1) .
To validate the 3D model of interaction proposed above, we first determined the affinities of the mutated receptors generated for the specific V 1b nonpeptide antagonist SSR149415. As shown in Fig. 4 and Table  2 , replacement in the hV 1a -R sequence of methionine 220 by a threonine residue increased the affinity of the mutant M220T for SSR149415 by 26-fold as compared with the wild-type hV 1a -R. Similarly, the A334M mutant also displayed a significant but more reduced shift of its affinity for the SSR149415 (8.9-fold gain in affinity as compared with the wild-type V 1a -R) (Fig. 4 and Table 2 ). The effects of these two single mutations were not additive because the double mutant M220T/ A334M displayed an affinity for SSR149415 similar to that determined for the A334M mutant (Table 2) . By contrast, the L181F mutant did not exhibit any significant gain in affinity for the specific V 1b antagonist ( Fig.  4 and Table 2 ). For the S338N mutant, we even observed a small (3.2-fold) decrease of affinity for the SSR149415 molecule. This decreased affinity could be explained by the probable loss of one hydrogen bond between the p-methoxy oxygen atom of the antagonist and the serine side chain, which is no longer possible with an asparagine (see Fig. 2 ).
We also decided to extend this pharmacological study to other specific AVP receptor-selective ligands. For the M220T mutant, the affinities of SR49059 and SR121463, two specific V 1a and V 2 nonpeptide antagonists, respectively (27, 28) , were significantly decreased as compared with the wild-type hV 1a -R ( Fig. 4 and Table 2 ). This was also the case for [
125 I]-HO-LVA, a specific peptide V 1a antagonist and d [Cha 4 ]AVP, a specific peptide V 1b agonist. Conversely, the affinity of F-180, a specific V 1a peptide agonist, was not significantly modified ( Fig. 4 and Table 2 ). The A334M mutant did not display such modifications. Its affinity for SR49049 was not strongly decreased. By contrast, that of SR121463 was significantly enhanced (6.2-fold gain in its affinity as compared with the wild-type hV 1a -R) ( Table 2 ). This mutant also exhibited a weak, but significant, increase of its affinity for the selective V 1b agonist d [Cha 4 ]AVP (4.2-fold increase as compared with the wild-type hV 1a -R) ( Fig. 4 and Table 2 ), and no modification for F-180. For the L181F and S338N mutants, no significant pharmacological differences concerning their affinities for the SR49059, SR121463, F-180, and d [Cha 4 ]AVP analogs were observed.
The ability of the M220T and A334M mutants to stimulate phospholipase C activity was further evaluated on Chinese hamster ovary (CHO)-transfected cells. Whatever the mutant considered (M220T or A334M), AVP was shown to stimulate accumulation of inositol phosphates (IPs) in a dose-dependent manner with the same activity constants (K act ) as compared with wild-type AVP receptors ( Fig. 5A and Table 3 ). The ability of SSR149415 to antagonize the AVP- The amino acid sequence of the human AVP receptor subtypes, V 1a (hV 1a -R) and V 1b (hV 1b -R), are compared with that of the bovine rhodopsin (OPSD BOVIN). TM helices (TM1-TM7) delimited by dark bars have been assigned as in the x-ray crystal structure of bovine rhodopsin (29) . E1-E3 and I1-I3 indicate the position of extracellular and intracellular loops, respectively. Thirty-two residues the side chains of which are directed toward the TM binding cavity are displayed in boldface. Among these 32 positions, nine residues enclosed by a box differ between the V 1a and V 1b receptor subtypes.
induced IP response was further investigated. As expected and illustrated on Fig. 5B , the potency of SSR149415 to inhibit AVP-stimulated IP accumulation was strongly affected as compared with CHO cells expressing wild-type AVP receptors. The inhibition constants (K inact ) of SSR149415 for M220T and A334M mutants were 36.5-and 4.6-fold reduced, respectively, as compared with wild-type hV 1a -R (Table 3) .
Potential Role of the E2 Loop in hV 1b -R Selectivity: a Chimeric Approach
The roles of some extracellular loops of the V 1a and V 2 receptors in ligand binding has been previously demonstrated (13, 15) . We thus hypothesized that the E2 loop may also be involved in the hV 1b -R selectivity because its amino acid sequence varied from one AVP receptor isoform to another. To validate this hypothe- sis, we replaced the wild-type hV 1a -R E2 loop by the hV 1b -R counterpart (Fig. 3) . Saturation binding experiments showed that the resulting chimeric receptor (V 1a /E2V 1b ) bound [ 3 H]AVP with a nanomolar affinity (Table 1) . Unfortunately, competition experiments did not reveal any significant modifications of its affinity whatever the selective VP analogs tested (Table 2) .
DISCUSSION
This study describes, for the first time, some structural features concerning the hV 1b -R and provides information about its interaction with the selective nonpeptide antagonist SSR149415.
First we developed a 3D molecular model of the hV 1b -R. This model integrates 1) the structural data from Palczewski et al. (29) concerning the bovine rhodopsin, the first crystallized GPCR and 2) information from the 3D model of the hV 1a -R recently published and validated (26) . The docking of SSR149415 into the hV 1b -R molecular model was performed as previously described for SR49059 into the hV 1a -R using the Gold program. From this interaction model, it was proposed that only four amino acid residues in close contact with SSR149415 and differing between the hV 1b and the hV 1a receptors may be potentially involved in the V 1b selectivity of SSR149415: Phe164, Thr203, Met324, and Asn328. Site-directed mutagenesis and analysis of the binding and functional properties of the resulting mutants revealed that Phe164, the side chain of which points outward of the binding crevice in our current V 1a and V 1b models, is not involved in the V 1b selectivity as well as Asn328. By contrast, Thr203 and/or the Met324 residues represent the minimal structural motif responsible for the selectivity of hV 1b -R for SSR149415. This selectivity derives probably from the abilities of the Thr203 and Met324 amino acids to establish H bond and hydrophobic interactions, respectively, with the SSR149415 compound as suggested by the interaction model proposed (see Fig. 2 ). We also might expect to observe an increase of the affinity of the double mutant for SSR149415. Its seems difficult to explain this nonadditivity of effects at the molecular level. Yet, as the M220T mutation contributes to enlarge the cavity around the TM5, whereas the A334M mutation limits the size of a remote subsite at TM7, it is possible that the double mutant undergoes small conformational rearrangements to optimize the packing of the TM7 bundle that slightly decreases the affinity of the selective V 1b antagonist SSR149415 for the double mutant. Interestingly, although the selective V 1a antagonist SR49059 and the selective V 1b antagonist SSR149415 share a common structure, they are proposed to bind to their cognate receptor in a very different manner (Fig. 6) . The indoline ring of SSR149415 is embedded in a hydrophobic pocket located between TMs 3 and 6, whereas the corresponding scaffold in SR49059 interacts mainly with TM5. Likewise, the dimethoxyphenyl moiety of SSR149415 is essentially directed toward TM7, whereas that of SR49059 mainly interacts with TMs 5 and 6 (Fig. 6) . Last, the prolinamide moieties of both antagonists are located in opposite directions in the TM cavity of both AVP receptors (Fig.  6) . The main two positions demonstrated to control V 1b selectivity are located at opposite extremities of the antagonist binding cavity (Thr203 on TM5, Met324 on TM7) and are spatially distant from approximately 18 Å (measured from the C␣ atoms). These two positions, 5.42 and 7.39 in the Ballesteros numbering (30), are key determinants of most GPCR antagonistbinding sites (31) .
The current V 1b -SSR149415 3D model, as well as the recently described V 1a -SR49059 model (38) , provides a good explanation for the herein reported mutation effects at the above cited two positions. Assuming a conserved binding mode of one individual antagonist to both receptors, the M220T mutation in the V 1a -R favors the binding of SSR149415 by creation of an additional H-bonding site for the prolinamide moiety, whereas the A334M mutation will reinforce the hydrophobic interactions to the dimethoxyphenyl group (Fig. 6) . Conversely, the latter mutations will disfavor binding of the selective V 1a antagonist SR49059 by increasing the size and hydrophilicity of the lipohilic cavity around its indoline ring (M220T mutation in V 1a residue numbering), and creating steric clashes with the prolinamide moiety (A334M).
Yet, both the M220T and A334M mutants, the affinity of which for SSR149415 is greatly increased, do not exhibit a significant modification of their K i for the natural hormone AVP and display only a small reduction in their affinities for SR49059 and [
125 I]-HO-LVA (see Table 2 ]AVP to a putative active state model of AVP receptors is necessary to validate these assumptions and to verify whether the specificity of the V 1b -R subtype could not be assumed by specific residues located within the lower part of the TM domains, generally known to affect the coupling properties. All together, these experiments suggest that a single mutation of the hV 1a -R may strongly affect its binding properties shifting from a V 1a to a V 1b pharmacological profile. This may also explain why the V 1a and V 1b receptor isoforms are phylogenetically so closed. In contrast to the V 2 -R isoform, they share the ability to activate phospholipases C via a G q/11 heterotrimeric G protein and differ especially by the structure of their binding site for antagonists such as SSR149415.
If the upper part of the TM helices of the group 1 GPCR family (including the AVP/OT receptors) are known to form a binding pocket for their specific ligands (32), a contribution of their extracellular loops to ligand selectivity has also been demonstrated. Hence the residue 115, located at the border between TM2 and the first extracellular domain, plays a key role in the pharmacological properties of the V 1a , V 2 , and oxytocin receptor subtypes (13) . Similarly, the E2 loop of the hV 2 -R isoform represents an important structural motif for discriminating between V 2 agonist and antagonist (15) . As the E2 loop from the three AVP receptor isoforms is quite different in terms of amino acid sequence, as compared with the first and third extracellular loops, we decided to verify whether this extracellular domain may control the ligand accessibility to the binding pocket (see Ref. 29) and could play a role in the hV 1b -R selectivity. A chimeric hV 1a -R, the E2 loop of which was replaced by that of the hV 1b -R (V 1a /E2V 1b ), was thus generated and tested for its binding selectivity. Despite a weak amino acid sequence homology between the hV 1a -R and hV 1b -R E2 loops (47%), no significant modification of the pharmacological properties of this chimera was observed as compared with the wild-type hV 1a -R. Yet, on the basis of these experiments performed at equilibrium, we cannot totally exclude a potential role of the E2 loop.
This structural information concerning the hV 1b -R with respect to those previously described for the V 1a and V 2 receptors, allow interesting comparisons regarding the binding site of specific AVP receptor antagonists. For the three AVP receptor subtypes, various peptide and nonpeptide antagonists were shown to interact with amino acids mainly located at the top of TM domains (15) (16) (17) 19) , suggesting that the binding sites of these ligands are localized in a binding cleft formed by the upper part of these ␣-helical domains. Interestingly, the amino acids responsible for the AVP receptors selectivity toward antagonists varied from one isoform to another. Thus, to date, we know that these residues are located on TM domains 5 and 7 for the V 1b -R (present study) on TM domains 2, 3, 4, 6, and 7 for the V 1a -R (16, 19) and restricted to the seventh helix for the V 2 -R (15).
Obviously, as indicated before, the knowledge of the residues of the V 1b -R allowing the binding discrimination between agonists and antagonists is also important. The results reported here clearly show that the Thr203 and Met324 residues are involved mainly in the binding of specific V 1b antagonist because the M220T and A334M V 1a mutants both exhibited strong increases in affinity for SSR149415 without important K d /K i modifications for AVP and d [Cha 4 ]AVP. Yet, further investigations will be necessary to accurately localize the molecular determinants that define agonist binding into the hV 1b -R.
In conclusion, these first results about the hV 1b -R functional architecture, allow a better virtual screening of new selective V 1b antagonists. Such new compounds are of potential therapeutic interest because, as previously observed, SSR149415, the first designed V 1b antagonist, reduced the level of stress and anxiety in the rat as efficiently as classical benzodiazepines with perhaps a safer profile (20) .
MATERIALS AND METHODS
Chemicals
Most standard chemicals were purchased from Sigma Chemical Co. The two main differing amino acids of the TM binding cavity are circled and displayed as solid sticks. (33) . DMEM, penicillin-streptomycin, Lglutamine, and nonessential amino acids were purchased from Invitrogen (Cergy Pontoise, France). Inositol-free DMEM came from ICN Biochemicals (Orsay, France). Dowex AG1-X8 (formate form, 200-400 mesh) was purchased from Bio-Rad Laboratories, Inc. (Munchen, Germany).
Alignment of Amino Acid Sequences
The amino acid sequences of the human V 1a and V 1b AVP receptor subtypes were retrieved from the Swiss-Prot database (accession nos.: V 1a -R, P37288; V 1b -R, P47901) and aligned to the sequence of bovine rhodopsin (accession no. P02699) using the in-house developed GPCRmod program (34) focusing on TM domains only. The alignment of the amino-and carboxy-terminal domains as well as of the intraand extracellular loops was realized using ClustalW (35) . A slow pair-wise alignment using BLOSUM matrix series (36) and a gap opening penalty of 15.0 were chosen for aligning the amino acid sequences to the sequence of bovine rhodopsin.
Modeling the Antagonist-Bound State of the hV 1b -R
The 3D model of the hV 1b -R was constructed from a previously reported model of the hV 1a -R (25) by mutating the side chains of the amino acids of the V 1a -R. Standard geometries for the mutated side chains were given by the BIOPOLYMER module of SYBYL (37). Whenever possible, the side chain torsional angles were kept to the values occurring in the V 1a -R model. Otherwise, a short scanning of side chain angles was performed to remove steric clashes between the mutated side chain and the other amino acids. The third intracellular loop between helices 5 and 6, which shows a high degree of variability, was not included in the model. This loop is probably not involved in direct interactions with the ligand as it was previously observed on the V 1a -R model (25) . We therefore assumed that omitting this loop should not influence our docking results. Insertions/deletions occurred only in loops but not in secondary structure elements (␣-helix, ␤-sheet). The insertions/deletions in the loops were achieved through a simple knowledge-based loop search procedure using the LOOPSEARCH module of the SYBYL package (37). In this procedure, a set of 1478 high-resolution x-ray structures was searched for loops of similar length and similar distance between the C␣ atoms of the residues delimiting the loop window. The loop showing the highest sequence identity and the lowest root-mean square (rms) deviations was then selected for insertion in the model. After the heavy atoms were modeled, all hydrogen atoms were added, and the protein coordinates were then minimized with AMBER (38) using the AMBER95 force field (39) . Topology and charge parameters for the nonpeptide V 1b antagonist were computed using a previously described procedure (40) . The minimizations were carried out by 1000 steps of steepest descent followed by conjugate gradient minimization until the rms gradient of the potential energy was less than 0.05 kcal/ mol.Å. A twin cut-off (10.0, 15.0 Å) was used to calculate nonbonded electrostatic interactions at every minimization step, and the nonbonded pair list was updated every 25 steps. A distance-dependent (⑀ ϭ 4r) dielectric function was used.
Automated Docking of a Selective V 1b Antagonist (SSR149415)
The Gold 1.2 docking program (41) was used to automatically dock the selective V 1b antagonist SSR149415. For each of the 10 independent genetic algorithm (GA) runs, a maximum number of 1000 GA operations was performed on a single population of 50 individuals. Operator weights for cross-over, mutation, and migration were set to 100, 100, and 0, respectively. To allow poor nonbonded contacts at the start of each GA run, the maximum distance between hydrogen donors and fitting points was set to 5 Å, and nonbonded van der Waals energies were cut off at a value equal to k ij (well depth of the van der Waals energy for the atom pair i,j). To further speed up the calculation, the GA docking was stopped when the top three solutions were within 1.5 Å rms deviations. If this criterion is met, we can assume that these top solutions represent a reproducible pose for the ligand.
Site-Directed Mutagenesis
All the mutations were generated into the hV 1a -R sequence. The pRK5 expression vector containing the hV 1a -R cDNA and the ampicillin resistance gene was kindly provided by Dr. B Mouillac. Amino acid replacements were generated by PCR using the QuikChange site-directed mutagenesis kit, according to the manufacturer's protocol (Stratagene, La Jolla, CA). For single-amino acid replacements (L181F, M220T, A334M, and S338N), cDNA of the wild-type hV 1a -R was used as the template with the appropriate mutated oligonucleotides primers. The double mutant M220T/A334M was generated as described above using cDNA of the M220T mutant as the template and mutated oligonucleotides primers corresponding to the A334M mutation. PCR products were transformed into the Escherichia coli XL-1 blue bacteria strain, and positive clones were selected under ampicillin selection. Plasmidic cDNAs of positive clones were then purified with the QIAprep Spin Miniprep Kit (QIAGEN, Courtaboeuf, France). All the mutations were verified by sequencing (Genome Express, Meylan, France). For further amplification of positive clones the E. coli DH 5 -␣ bacteria strain (Invitrogen) was used.
Construction of the Chimeric V 1a -R Containing the V 1b E2 Loop
Modifications were performed in the hV 1a -R cDNA inserted into the pRK5 expression vector containing the ampicillin resistance gene. AflII and XhoI enzymatic cleavage sites were respectively introduced at the 3Ј-and 5Ј-ends of the E2 loop of the hV 1a -R cDNA by site-directed mutagenesis with the appropriate oligonucleotides primers. These mutations were silent because they did not modify the amino acid sequence of the wild-type V 1a -R. Specific digestion of each side of the V 1a E2 loop with appropriate restriction enzymes was done, and an oligonucleotide sequence corresponding to the E2 loop of the hV 1b -R was then introduced by T4 ligase treatment. Each construct was transformed, grown, and ampicillin selected into the E. coli DH 5 -␣ bacteria strain. All the constructs were verified by sequencing (Genome Express).
cDNA Expression of Wild-Type and Mutant AVP Receptors and Cell Culture
The human V 1a and V 1b wild-type receptors were stably expressed in Chinese Hamster Ovary cells (CHO) as previously described (16) . The mutants and chimera of the hV 1a -R were transiently expressed in CHO cells by electroporation. Briefly, the cells (10 7 /0.3 ml) were suspended in an electroporation buffer containing: 50 mM K 2 HPO 4 ; 20 mM C 2 H 3 KO 2 ; 20 mM KOH, pH 7.4; 20 g of carrier DNA (pRK5 expression vector without any insert); 0.5-2g of the expression vector containing the mutated receptor cDNA and 40 mM MgSO 4 ; and then incubated for 20 min at room temperature before being pulsed (280 V, 950 F, Bio-Rad Apparatus).
The CHO cells expressing the wild-type and mutated AVP receptors were plated in 150-mm Petri dishes or 24-well plates depending upon the experiment to be conducted. Cells were maintained in culture in DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 500 U/ml penicillin and streptomycin, and nonessential amino acids in an atmosphere of 95% air and 5% CO2 at 37 C. Cells were used 48 h after seeding both for binding and functional assays.
Membrane Preparations
CHO cells stably or transiently transfected with the wild-type or the mutated AVP receptors were harvested, washed two times in PBS without calcium and magnesium, Polytron homogenized in lysis buffer (15 mM Tris-HCl, pH 7.4; 2 mM MgCl 2 , 0.3 mM EDTA), and centrifuged at 100 ϫ g for 5 min at 4 C. The supernatants were recovered and centrifuged at 44,000 ϫ g for 20 min at 4 C. The pellets were washed in 50 mM Tris-HCl (pH 7.4)-3 mM MgCl 2 (buffer A) and centrifuged at 44,000 ϫ g for 20 min at 4 C. The membranes were suspended in a small volume of buffer A and their protein contents were determined. Aliquots of membranes were used immediately or stored at Ϫ80 C.
Radioligand-Binding Assay
Membrane-binding assays were performed at 30 C as described previously (42) ) for the wild-type and the mutated AVP receptors were determined in saturation experiments using concentrations ranging from 0.1 to 10 nM and 10 to 1500 pM, respectively. For each concentration of radioligand, total and nonspecific binding were determined in the absence or presence of 1 M of unlabeled AVP, respectively. Affinities of the unlabeled ligands (K i ) were determined in competition experiments using 0.5 to 1 nM [ 3 H]AVP (a concentration close to the K d value of the wild-type or the mutated receptors studied) and increasing concentrations of the unlabeled analogs to be tested (0.1 nM to 10 M). Radioactivity found associated to plasma membranes was determined by filtration through GF/C filters, and specific binding was calculated as previously described (42) .
IP Assays
Total IP accumulation was determined as previously described (43) . Briefly, CHO cells stably or transiently transfected with the wild-type and the mutated receptors were grown for 24 h in DMEM supplemented with 10% fetal calf serum. Cells were further incubated for another 24-h period in a serum and inositol-free medium supplemented with 1 Ci⅐ml Ϫ1 myo-[2-3 H]inositol. Cells were then washed twice with a Hanks' buffered saline (HBS) medium. For stimulation experiments, the cells were preincubated for 15 min in HBS supplemented with 20 mM LiCl and further stimulated for 15 min with the agonists to be tested. For inhibition experiments, the cells were preincubated 15 min with HBS/LiCl medium supplemented with the antagonist to be tested and further stimulated for 15 min with 1 nM AVP. The reaction was stopped by adding perchloric acid (5% vol/vol). Total IPs accumulated were extracted, purified on Dowex AG1-X8 anion exchange chromatography column, and counted.
Data Analysis
The radioligand binding data were analyzed by GraphPad Prism (GraphPad Software, Inc., San Diego, CA). The K d values of the radioligands were determined according to the Scatchard linearization of the saturation curve obtained (44 
